Michael Megna Sells 50,490 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock

Key Points

• Michael Megna, CAO of Kiniksa Pharmaceuticals, sold 50,490 shares of the company's stock for approximately $1.96 million, reducing his ownership by 65.12%.
• The stock price of Kiniksa Pharmaceuticals rose 0.1% to $38.90, with a market capitalization of $2.88 billion and a noted 52-week high of $39.79.
• Kiniksa reported an earnings beat in its last quarter with $0.23 EPS against a consensus estimate of $0.18, and analysts remain optimistic with a consensus target price of $46.86.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) CAO Michael Megna sold 50,490 shares of the company's stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $38.87, for a total transaction of $1,962,546.30. Following the transaction, the chief accounting officer owned 27,046 shares in the company, valued at $1,051,278.02. The trade was a 65.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Kiniksa Pharmaceuticals International Stock Up 0.1%

NASDAQ:KNSA traded up $0.05 during mid-day trading on Wednesday, hitting $38.90. 422,040 shares of the stock traded hands, compared to its average volume of 631,092. The stock has a market capitalization of $2.88 billion, a price-to-earnings ratio of 972.74 and a beta of 0.16. Kiniksa Pharmaceuticals International, plc has a 52 week low of $17.82 and a 52 week high of $39.79. The firm's 50 day moving average is $36.10 and its two-hundred day moving average is $30.02.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, beating the consensus estimate of $0.18 by $0.05. The company had revenue of $156.80 million for the quarter, compared to the consensus estimate of $145.21 million. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. As a group, research analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Hedge funds have recently modified their holdings of the business. USA Financial Formulas purchased a new stake in shares of Kiniksa Pharmaceuticals International in the 3rd quarter worth approximately $32,000. EverSource Wealth Advisors LLC lifted its position in shares of Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company's stock worth $25,000 after purchasing an additional 532 shares during the period. Osaic Holdings Inc. purchased a new stake in shares of Kiniksa Pharmaceuticals International in the 2nd quarter worth approximately $31,000. GAMMA Investing LLC lifted its position in shares of Kiniksa Pharmaceuticals International by 84.8% in the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock worth $27,000 after purchasing an additional 568 shares during the period. Finally, Farther Finance Advisors LLC lifted its position in shares of Kiniksa Pharmaceuticals International by 582.4% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,358 shares of the company's stock worth $53,000 after purchasing an additional 1,159 shares during the period. Hedge funds and other institutional investors own 53.95% of the company's stock.

Wall Street Analyst Weigh In

KNSA has been the subject of several research reports. Zacks Research cut shares of Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "hold" rating in a research report on Monday, October 6th. Citigroup boosted their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the company a "buy" rating in a research report on Friday, October 17th. Jefferies Financial Group boosted their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a research report on Tuesday, July 29th. Wall Street Zen cut shares of Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a research report on Friday, October 3rd. Finally, TD Cowen initiated coverage on shares of Kiniksa Pharmaceuticals International in a research report on Monday, September 29th. They issued a "buy" rating and a $60.00 price objective for the company. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, Kiniksa Pharmaceuticals International currently has an average rating of "Moderate Buy" and a consensus target price of $46.86.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.